- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2013
- Public Summary Document (PSD) November 2013 PBAC Meeting - PDF
Bevacizumab – November 2013
Bevacizumab, solution for IV use, 100mg in 4mL and 400mg in 16mL, Avastin®
Last updated
8 November 2023